Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Drops By 57.4%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 14,600 shares, a decline of 57.4% from the October 31st total of 34,300 shares. Based on an average daily volume of 254,600 shares, the days-to-cover ratio is presently 0.1 days.

Chugai Pharmaceutical Stock Up 3.8 %

OTCMKTS CHGCY traded up $0.80 during trading on Thursday, hitting $21.63. 56,222 shares of the stock traded hands, compared to its average volume of 128,906. The company has a market capitalization of $71.16 billion, a P/E ratio of 27.73 and a beta of 0.89. Chugai Pharmaceutical has a 12-month low of $14.52 and a 12-month high of $26.00. The firm has a 50-day simple moving average of $23.30 and a 200-day simple moving average of $20.80.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.